Periodontal tissue inflammation

Periodontal tissue inflammation is a chronic inflammatory condition affecting the tissues that support the teeth, including the gingiva, periodontal ligament, and alveolar bone (StatPearls, 2023). It is initiated by the accumulation of a dysbiotic bacterial biofilm on the tooth surface, which triggers a robust host immune response involving the recruitment of neutrophils and macrophages (NIH, 2023). This response leads to the production of pro-inflammatory cytokines like TNF-α and IL-1β, and enzymes such as matrix metalloproteinases (MMPs) that degrade the extracellular matrix (PubMed, 2021). If left unresolved, the persistent inflammation leads to the destruction of the periodontal ligament and resorption of the alveolar bone, eventually resulting in tooth loss (Journal of Periodontology, 2022). Pharmacological management focuses on reducing the microbial burden and modulating the host response, such as using sub-antimicrobial dose doxycycline to inhibit MMP activity, to prevent further tissue damage (FDA, 2005). While not a single molecular target, the inflammatory process involves multiple pathways that are targeted by various therapeutic agents to arrest disease progression.

Other names

PeriodontitisGingivitisPeriodontal diseaseGum inflammationPeriodontal inflammation

Therapeutic interventions for periodontal tissue inflammation primarily involve antimicrobial action to reduce the bacterial load (e.g., chlorhexidine, minocycline), inhibition of host-derived tissue-destructive enzymes like matrix metalloproteinases (MMPs) (e.g., sub-antimicrobial dose doxycycline), and suppression of pro-inflammatory mediators such as prostaglandins via cyclooxygenase inhibition (e.g., flurbiprofen) (StatPearls, 2023; FDA, 2005).